Display options
Cite
Yandamuri SS, Lane TE. Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis. Front Immunol. 2016;7:189doi: 10.3389/fimmu.2016.00189.
Yandamuri, S. S., & Lane, T. E. (2016). Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis. Frontiers in immunology, 7189. https://doi.org/10.3389/fimmu.2016.00189
Yandamuri, Soumya S, and Lane, Thomas E. "Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis." Frontiers in immunology vol. 7 (2016): 189. doi: https://doi.org/10.3389/fimmu.2016.00189
Yandamuri SS, Lane TE. Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis. Front Immunol. 2016 May 19;7:189. doi: 10.3389/fimmu.2016.00189. eCollection 2016. PMID: 27242796; PMCID: PMC4871863.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2016 May 19;7:189. doi: 10.3389/fimmu.2016.00189. eCollection 2016.

Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis.

Frontiers in immunology

Soumya S Yandamuri, Thomas E Lane

Affiliations

  1. Department of Bioengineering, University of Utah , Salt Lake City, UT , USA.
  2. Department of Bioengineering, University of Utah, Salt Lake City, UT, USA; Department of Pathology, School of Medicine, University of Utah, Salt Lake City, UT, USA.

PMID: 27242796 PMCID: PMC4871863 DOI: 10.3389/fimmu.2016.00189

Abstract

Multiple sclerosis (MS) is a central nervous system (CNS) disease characterized by chronic neuroinflammation, demyelination, and axonal damage. Infiltration of activated lymphocytes and myeloid cells are thought to be primarily responsible for white matter damage and axonopathy. Over time, this neurologic damage manifests clinically as debilitating motor and cognitive symptoms. Existing MS therapies focus on symptom relief and delay of disease progression through reduction of neuroinflammation. However, long-term strategies to remyelinate, protect, or regenerate axons have remained elusive, posing a challenge to treating progressive forms of MS. Preclinical mouse models and techniques, such as immunohistochemistry, flow cytometry, and genomic and proteomic analysis have provided advances in our understanding of discrete time-points of pathology following disease induction. More recently, in vivo and in situ two-photon (2P) microscopy has made it possible to visualize continuous real-time cellular behavior and structural changes occurring within the CNS during neuropathology. Research utilizing 2P imaging to study axonopathy in neuroinflammatory demyelinating disease has focused on five areas: (1) axonal morphologic changes, (2) organelle transport and health, (3) relationship to inflammation, (4) neuronal excitotoxicity, and (5) regenerative therapies. 2P imaging may also be used to identify novel therapeutic targets via identification and clarification of dynamic cellular and molecular mechanisms of axonal regeneration and remyelination. Here, we review tools that have made 2P accessible for imaging neuropathologies and advances in our understanding of axonal degeneration and repair in preclinical models of demyelinating diseases.

Keywords: animal models; axonal damage; multiple sclerosis; remyelination; two-photon microscopy

References

  1. Brain Pathol. 2008 Jan;18(1):52-61 - PubMed
  2. FEBS Lett. 1994 May 23;345(1):50-4 - PubMed
  3. Chem Immunol. 1989;46:101-25 - PubMed
  4. Nat Methods. 2007 Feb;4(2):127-9 - PubMed
  5. Nat Methods. 2008 Sep;5(9):805-11 - PubMed
  6. J Exp Med. 2015 Jan 12;212(1):23-35 - PubMed
  7. Ann Neurol. 2009 Feb;65(2):151-9 - PubMed
  8. Exp Neurol. 2004 Jun;187(2):254-65 - PubMed
  9. Eur J Immunol. 2006 Mar;36(3):671-80 - PubMed
  10. Cell. 2014 Aug 14;158(4):945-58 - PubMed
  11. Stem Cells Transl Med. 2012 Jul;1(7):536-47 - PubMed
  12. J Neurol Sci. 2003 Feb 15;206(2):165-71 - PubMed
  13. N Engl J Med. 1998 Jan 29;338(5):323-5 - PubMed
  14. Neurochem Res. 1994 Aug;19(8):915-21 - PubMed
  15. Arch Neurol. 2003 Aug;60(8):1082-8 - PubMed
  16. J Clin Invest. 2008 Apr;118(4):1532-43 - PubMed
  17. Methods. 1999 Jun;18(2):231-9, 181 - PubMed
  18. Crit Rev Immunol. 2010;30(2):119-30 - PubMed
  19. Nat Neurosci. 2011 Aug 30;14(11):1481-8 - PubMed
  20. Brain. 2006 Dec;129(Pt 12):3186-95 - PubMed
  21. J Neurochem. 2016 Mar;136(5):971-80 - PubMed
  22. Curr Opin Neurol. 2001 Jun;14(3):271-8 - PubMed
  23. Nat Med. 2011 Apr;17(4):495-9 - PubMed
  24. Science. 2002 Jun 7;296(5574):1869-73 - PubMed
  25. Neurochem Res. 1994 Aug;19(8):935-44 - PubMed
  26. Brain. 1995 Dec;118 ( Pt 6):1583-92 - PubMed
  27. Neurology. 2000 Jan 11;54(1):15-9 - PubMed
  28. Lancet Neurol. 2002 Aug;1(4):232-41 - PubMed
  29. Trends Neurosci. 2002 Jun;25(6):313-9 - PubMed
  30. Brain. 1989 Feb;112 ( Pt 1):133-46 - PubMed
  31. J Neurosci. 1998 Mar 15;18(6):1953-62 - PubMed
  32. J Virol. 2001 Jul;75(13):6115-20 - PubMed
  33. J Neurol Sci. 2005 Jun 15;233(1-2):133-8 - PubMed
  34. Science. 1946 Oct 18;104(2703):362-3 - PubMed
  35. Ann Neurol. 2001 Sep;50(3):389-400 - PubMed
  36. J Neuropathol Exp Neurol. 2007 Sep;66(9):828-37 - PubMed
  37. J Exp Med. 2007 Oct 1;204(10):2363-72 - PubMed
  38. Neurol Clin. 2008 Aug;26(3):699-715, viii - PubMed
  39. Exp Neurol. 2010 Nov;226(1):148-58 - PubMed
  40. Neurology. 2003 Oct 28;61(8):1113-20 - PubMed
  41. Stem Cells Dev. 2011 Dec;20(12):2065-76 - PubMed
  42. Mult Scler. 1999 Oct;5(5):355-62 - PubMed
  43. Proc Natl Acad Sci U S A. 2005 May 3;102(18):6437-42 - PubMed
  44. Lancet. 2002 Apr 6;359(9313):1221-31 - PubMed
  45. Mol Med. 1997 Nov;3(11):750-64 - PubMed
  46. Brain. 2005 May;128(Pt 5):979-87 - PubMed
  47. Brain. 2002 Oct;125(Pt 10):2202-12 - PubMed
  48. Nat Med. 2000 Jan;6(1):67-70 - PubMed
  49. Nat Methods. 2013 Jun;10(6):508-13 - PubMed
  50. Immunity. 2010 Sep 24;33(3):424-36 - PubMed
  51. Nat Med. 2005 May;11(5):572-7 - PubMed
  52. J Exp Med. 1933 Jun 30;58(1):39-53 - PubMed
  53. J Neurosci Methods. 2015 Jul 15;249:8-15 - PubMed
  54. AJNR Am J Neuroradiol. 2007 Feb;28(2):272-7 - PubMed
  55. Nat Rev Neurosci. 2008 Nov;9(11):839-55 - PubMed
  56. Nat Protoc. 2006;1(3):1057-65 - PubMed
  57. Ann Neurol. 1981 Aug;10(2):149-58 - PubMed
  58. Nat Protoc. 2013 Mar;8(3):481-90 - PubMed
  59. J Neuropathol Exp Neurol. 2011 Nov;70(11):1020-35 - PubMed
  60. Neurobiol Dis. 2008 May;30(2):162-73 - PubMed
  61. J Virol. 1999 Oct;73(10):8771-80 - PubMed
  62. Magn Reson Med. 2007 Apr;57(4):688-95 - PubMed
  63. Neurobiol Dis. 2006 Mar;21(3):626-32 - PubMed
  64. N Engl J Med. 2002 Jan 17;346(3):165-73 - PubMed
  65. Proc Natl Acad Sci U S A. 2004 May 25;101(21):8168-73 - PubMed
  66. Curr Protoc Immunol. 2007 May;Chapter 15:Unit 15.1 - PubMed
  67. Ann Neurol. 2001 Aug;50(2):169-80 - PubMed
  68. J Exp Med. 1960 Jan 1;111:119-36 - PubMed
  69. Brain. 2008 Jul;131(Pt 7):1722-35 - PubMed
  70. Nat Commun. 2014 Sep 12;5:4827 - PubMed
  71. Sci Transl Med. 2012 Oct 10;4(155):155ra137 - PubMed
  72. Brain. 1996 Jun;119 ( Pt 3):701-8 - PubMed
  73. Ann Neurol. 2006 Mar;59(3):478-89 - PubMed
  74. FEBS Lett. 1994 Dec 19;356(2-3):295-8 - PubMed
  75. Neurology. 2001 Oct 9;57(7):1248-52 - PubMed
  76. Isr J Med Sci. 1981 Aug;17(8):711-4 - PubMed
  77. Acta Neuropathol. 1987;73(3):259-66 - PubMed
  78. Brain. 2007 Nov;130(Pt 11):2800-15 - PubMed
  79. Neuron. 2014 Dec 17;84(6):1183-90 - PubMed
  80. Ann Neurol. 2001 Apr;49(4):470-6 - PubMed
  81. Glia. 2005 Aug 15;51(3):235-40 - PubMed
  82. J Neurosci. 2004 Mar 10;24(10):2458-64 - PubMed
  83. J Bacteriol. 1946 May;51:614 - PubMed
  84. Brain. 2009 May;132(Pt 5):1161-74 - PubMed
  85. N Engl J Med. 1998 Jan 29;338(5):278-85 - PubMed
  86. Ann Neurol. 2009 Feb;65(2):160-6 - PubMed
  87. J Neurosci. 1999 Jan 1;19(1):147-58 - PubMed
  88. Brain. 1997 Mar;120 ( Pt 3):393-9 - PubMed
  89. J Neuroimmunol. 2013 Aug 15;261(1-2):67-76 - PubMed
  90. J Immunol. 1994 Nov 15;153(10):4349-56 - PubMed
  91. J Exp Med. 1994 Sep 1;180(3):817-29 - PubMed
  92. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):E2349-55 - PubMed
  93. Science. 1998 Jun 5;280(5369):1610-3 - PubMed
  94. Brain. 1996 Dec;119 ( Pt 6):2009-19 - PubMed
  95. Eur J Immunol. 1995 Apr;25(4):985-93 - PubMed
  96. Ann N Y Acad Sci. 1985;455:552-62 - PubMed
  97. J Exp Med. 2005 Jun 6;201(11):1805-14 - PubMed
  98. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18625-30 - PubMed
  99. J Immunol. 2002 Jul 1;169(1):117-25 - PubMed
  100. Arch Neurol. 2001 Jan;58(1):65-70 - PubMed
  101. Ann Neurol. 2007 Apr;61(4):288-99 - PubMed
  102. Eur J Immunol. 2009 Aug;39(8):2031-5 - PubMed
  103. Am J Pathol. 2000 Jul;157(1):267-76 - PubMed
  104. Nat Med. 2000 Jan;6(1):62-6 - PubMed
  105. Nat Rev Neurosci. 2006 Dec;7(12):932-41 - PubMed
  106. J Neurol Sci. 2012 Feb 15;313(1-2):167-77 - PubMed
  107. J Neurochem. 1997 Jun;68(6):2227-40 - PubMed
  108. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7631-6 - PubMed
  109. J Neuroimmunol. 1983 Jun;4(3):201-21 - PubMed
  110. Physiology (Bethesda). 2007 Dec;22:358-65 - PubMed
  111. Brain Pathol. 2007 Apr;17(2):210-8 - PubMed

Publication Types

Grant support